ライフサイエンスコーパス: arthralgia

1 rus, and a small number developed persistent arthralgia.

2 ncluded keratoacanthomas, rash, fatigue, and arthralgia.

3 atient cohorts of CHIKV load associated with arthralgia.

4 ver, chills, marked headache, and myalgia or arthralgia.

5 ammatory mediators during alphavirus-induced arthralgia.

6 ood, some develop debilitating and prolonged arthralgia.

7 rus faster and did not experience persistent arthralgia.

8 se or as a rheumatic symptom such as diffuse arthralgia.

9 e limited by grade 2 or 3 rash, fatigue, and arthralgia.

10 s characterized by rash, conjunctivitis, and arthralgia.

11 ome and sirolimus-associated pneumonitis and arthralgia.

12 openia, stomatitis/pharyngitis, myalgia, and arthralgia.

13 eterious side effects, such as bone loss and arthralgia.

14 cluded chills, fever, fatigue, headache, and arthralgia.

15 greater than 1 pound is a valid test for TMJ arthralgia.

16 nate between subjects with and those without arthralgia.

17 PT) of 1 pound for the identification of TMJ arthralgia.

18 epicted effusions identify patients with TMJ arthralgia.

19 eactions, fever, chills, abdominal pain, and arthralgia.

20 hyperbilirubinemia, skin rash, myalgia, and arthralgia.

21 ing hepatitis, cervical lymphadenopathy, and arthralgia.

22 ients with chronic unspecified arthritis and arthralgia.

23 ver, chills, headache, fatigue, myalgia, and arthralgia.

24 roups were ulcerative colitis, COVID-19, and arthralgia.

25 etimes trigger temporomandibular joint (TMJ) arthralgia.

26 irus and a small number developed persistent arthralgia.

27 y symptoms and 14 (43.8%) evolved to chronic arthralgia.

28 roids use did not relate with AKI or chronic arthralgia.

29 n southern Vietnam with fever, headache, and arthralgia.

30 fection is a highly debilitating and chronic arthralgia.

31 luding fever, headache, chills, myalgia, and arthralgia.

32 s were fatigue, loss of smell and taste, and arthralgias.

33 had a lower overall incidence of chills and arthralgias.

34 ar symptoms, uveitis, auditory symptoms, and arthralgias.

35 a (14%), diarrhea (12%), pruritus (12%), and arthralgia (10%).

36 ]), liver function abnormalities (165 [5%]), arthralgia (106 [3%]), and fatigue (93 [3%]).

37 %]), injection-site reaction (12 [17%]), and arthralgia (11 [15%]).

38 ]), influenza (15 [6%]), vomiting (13 [5%]), arthralgia (11 [5%]), irritability (ten [4%]), fatigue (

39 The most common adverse events were arthralgia (12 [11%] patients in the placebo group and 2

40 ts of all grades included rash (1592 [49%]), arthralgia (1259 [39%]), fatigue (1093 [34%]), photosens

41 40 patients vs three [17%] of 18 patients), arthralgia (13 [33%] vs two [11%]), and diarrhoea (12 [3

42 e pyrexia (19%), rash (17%), pain (13%), and arthralgia (13%).

43 2411 in the continuous letrozole group) and arthralgia (136 [6%] vs 151 [6%]).

44 with placebo were neutropenia (15% vs. 0%), arthralgia (15% vs. 5%), and diarrhea (12% vs. 2%).

45 All presented arthralgia, 15 (46.9%) with joint inflammatory symptoms

46 cidences of AEs of interest (days 1-42) were arthralgia (17.1% combined lots, 20.4% high-dose, 3.0% p

47 ]), constipation (23 [13%] vs 25 [13%]), and arthralgia (18 [10%] vs 30 [16%]).

48 to prior KI discontinuation were rash (27%), arthralgia (18%), and atrial fibrillation (16%).

49 (34%), infusion-related reactions (34%), and arthralgias (18%).

50 Crohn's disease (35 [29%] of 122 patients), arthralgia (19 [16%]), and nasopharyngitis (18 [15%]) in

51 iculty (2.2-fold), cough (2.2-fold), myalgia/arthralgia (2-fold), and diarrhea (1.4-fold) as signific

52 ith administration (1/12), delayed transient arthralgia (2/12), and mild marrow suppression (calculat

53 difficulty sleeping (1.9, 1.3-2.8; p=0.001), arthralgias (2.0, 1.1-3.6; p=0.020), and various constit

54 hypercalcaemia (two [<1%] vs 22 [10%]), and arthralgia (22 [10%] vs 13 [6%]).

55 Carpal tunnel syndrome (33%), arthralgia (25%), and dermato-neuro syndrome (DNS) (18%)

56 igue (91%), fever (82%), headache (59%), and arthralgia (29%); onset clustered during 2 distinct peri

57 iarrhea (11%), nausea/vomiting (5%), myalgia/arthralgia (3%), and sensory neuropathy (3%).

58 ported for letrozole versus anastrozole were arthralgia (3.9% v 3.3%, and 48.2% v 47.9% for all adver

59 ), fatigue (41%), cough (39%), nausea (32%), arthralgia (31%), peripheral edema (31%), and hypertensi

60 The most common AEs were arthralgia (33%), hyperkeratosis (27%), and pyrexia (24%

61 The most common adverse events were arthralgia (38 [17%] in the fulvestrant group vs 24 [10%

62 (59 [26%]), nasopharyngitis (47 [21%]), and arthralgia (39 [17%]).

63 (42.2% vs 46.6%), rash (40.9%, both groups), arthralgia (39.1% vs 28.1%), pyrexia (38.7% vs 26.0%), a

64 %] vs 3 [4%]), back pain (4 [5%] vs 3 [4%]), arthralgia (4 [5%] vs 1 [1%]), and nausea and vomiting (

65 The most common grade 3 adverse events were arthralgia (47 [2%] of 1933 patients in the placebo grou

66 ne pain (5 years, 8.3% vs 2 years, 3.7%) and arthralgia (5 years, 5.1% vs 2 years, 3.1%).

67 st common adverse events were fatigue (50%), arthralgias (53%), and hot flashes (59%).

68 ined from a patient with chronic myalgia and arthralgia 6 months after acute SINV infection and asses

69 s included exanthema (88%), fever (76%), and arthralgia (72%).

70 such symptoms as fever (94%) and myalgia or arthralgia (78%).

71 upper respiratory tract infection (8%), and arthralgia (8%).

72 and the apheresis process included myalgias/arthralgias (83%), headache (44%), fever (27%), and chil

73 ncer survivors receiving an AI and reporting arthralgia, a yearlong randomized trial of the impact of

74 (fever/chills, nausea/vomiting, and myalgias/arthralgias), acute infusion-related events (hypotension

75 reatment AEs were considered, thrombosis and arthralgia AEs were associated with discontinuation of b

76 CHIKV may cause long-lasting arthralgia after acute infection.

77 Forty patients with chronic chikungunya arthralgia and 40 patients with RA were enrolled in a cr

78 Mechanisms underlying alphavirus-induced arthralgia and arthritis are not clearly understood, tho

79 iated with outbreaks of acute and persistent arthralgia and arthritis in humans.

80 ebrile illness characterized by debilitating arthralgia and arthritis that can endure for months to y

81 Joint symptoms (eg, arthralgia and arthritis) are a well-known side-effect o

82 eumatologic conditions owing to non-specific arthralgia and back pain.

83 Patients experienced fever, skin rash, arthralgia and conjunctivitis.

84 -specific symptoms (fever, malaise, myalgia, arthralgia and disturbances of smell or taste).

85 Both the arthralgia and fever did not relapse, and anti-ds DNA an

86 On admission, the arthralgia and fever spontaneously resolved, and there w

87 effects included fatigue, myalgia, headache, arthralgia and fever.

88 ecological problems and vascular events, but arthralgia and fractures were increased.

89 Two dose-limiting toxicities (DLTs; grade 3 arthralgia and grade 3 fatigue) were reported in the ini

90 d; however, there was increased incidence of arthralgia and joint stiffness without significant incre

91 to cause explosive outbreaks of debilitating arthralgia and myalgia in human populations.

92 Chikungunya fever is characterized by severe arthralgia and myalgia that can persist for years and ha

93 e 3 stomatitis and fatigue and one developed arthralgia and myalgia.

94 e rash and arthritis and sometimes prolonged arthralgia and myalgia.

95 igh spiking fevers, leukocytosis, skin rash, arthralgia and myalgia.

96 ith (n = 19) or without (n = 18) sequelae of arthralgia and ocular symptoms.

97 The main adverse events were arthralgia and other aromatase-inhibitor related symptom

98 nfection (22%), peripheral neuropathy (17%), arthralgia and pain (17%), stomatitis (12%), fatigue (10

99 ack adequate specificity for identifying TMJ arthralgia and were not associated with pain.

100 se events compared with placebo, except that arthralgias and chest pain were worse in those receiving

101 uropathy (n = 6), transaminitis (n = 1), and arthralgias and fatigue (n = 2).

102 of grade 2 constitutional symptoms (myalgias/arthralgias and fatigue) at 75 micrograms/kg, dose escal

103 Grade III myalgias/arthralgias and headaches required dose reduction of SAF

104 Arthralgias and myalgia were reported significantly more

105 ioids were required for treatment-associated arthralgias and/or myalgias during 17 of 52 treatment co

106 lated to nerve pathology as opposed to being arthralgias and/or myalgias.

107 controls (conjunctivitis, eosinophilia, and arthralgia) and exposure controls (other medications wit

108 ation between MRI-depicted effusions and TMJ arthralgia, and (2) a PPT of 1 pound does not discrimina

109 lgia only, 157 with both myofascial pain and arthralgia, and 195 controls without TMD pain met criter

110 children had rash, 104 (74%) fever, 67 (48%) arthralgia, and 51 (36%) conjunctivitis.

111 ection-site reactions, upper abdominal pain, arthralgia, and asthenia were more common in the 2-mg an

112 , including urticarial rash, fever episodes, arthralgia, and bone and muscle pain with cryopyrin-asso

113 itzler syndrome with urticarial rash, fever, arthralgia, and bone pain; 47% reported weight loss, 40%

114 Rash, fever, arthralgia, and conjunctivitis were common symptoms.

115 miting illness characterised by fever, rash, arthralgia, and conjunctivitis.

116 lipidemia, neutropenia, fatigue, leukopenia, arthralgia, and diarrhea were more frequent in the bexar

117 ly mild, systemic reactions (abdominal pain, arthralgia, and diarrhea).

118 a patient with a history of recurrent fever, arthralgia, and disseminated skin lesions.

119 isease, clinical sequelae including uveitis, arthralgia, and fatigue are common and necessitate syste

120 characterised by recurrent episodes of rash, arthralgia, and fever after cold exposure.

121 effects included fatigue, myalgia, headache, arthralgia, and fever.

122 tment groups were worsening Crohn's disease, arthralgia, and headache.

123 ents with lasofoxifene were nausea, fatigue, arthralgia, and hot flushes.

124 ammatory disorders that cause rashes, fever, arthralgia, and in some subjects, AA amyloidosis, and ha

125 ly less grade >/= 3 neuropathy, neutropenia, arthralgia, and myalgia occurred in the nab-PC arm, and

126 Fever, arthralgia, and myalgia were more common in older childr

127 were associated with tendinopathy, myalgia, arthralgia, and nausea.

128 n with combination therapy, whereas myalgia, arthralgia, and neutropenic fever/sepsis were more commo

129 3 hypertriglyceridemia, two grade 3 myalgia/arthralgia, and one grade 3 fatigue.

130 g musculoskeletal pain, bone pain, headache, arthralgia, and pain in extremity, in cancer patients.

131 ropathy, myalgia, nausea, fatigue, headache, arthralgia, and vomiting.

132 h travel to Haiti who developed fever, rash, arthralgias, and conjunctivitis.

133 s fever, chills, headache, malaise, fatigue, arthralgias, and myalgias) before randomization.

134 and warmth) and systemic reactions (chills, arthralgias, and myalgias) in the vaccine group than in

135 eroids who presented with urinary retention, arthralgias, and peripheral edema, subsequently develope

136 6]), hypertension, obstructive lung disease, arthralgias, and peripheral neuropathy.

137 logic toxicities, including nausea, fatigue, arthralgias, and peripheral sensory neuropathy, were mil

138 reactogenicity (local pain/soreness, chills, arthralgia, anorexia, and malaise).

139 hikungunya virus (CHIKV) is a mosquito-borne arthralgia arbovirus that is reemergent in sub-Saharan A

140 l presentations of these agents are similar, arthralgias are highly suggestive of CHIKV infection.

141 ammation as measured by MRI in ACPA positive arthralgia (ARIAA) study is a randomised, international,

142 Arthralgia, arthritis, edema, and myalgia were more comm

143 c disease phase, which may include long-term arthralgia, arthritis, fatigue, and depression.

144 enzyme increased, dizziness, aphthous ulcer, arthralgia, arthritis, increased appetite, increased wei

145 Complications include arthralgia, arthritis, thrombocytopenic purpura, and enc

146 eatures of this syndrome are malar eruption, arthralgias, arthritis, and laboratory abnormalities inc

147 commonly affected organs, patients may have arthralgias, arthritis, oesophageal disease, or cardiopu

148 Manifestations of SLE such as fatigue, arthralgia/arthritis, and serositis responded particular

149 Joint symptoms were defined as any report of arthralgia, arthrosis, arthritis, or joint disorder on a

150 dy that associated levels of CHIKV load with arthralgia as an indicator of acute CHIKV infection.

151 y identified recent fever, night sweats, and arthralgias as symptoms that may be predictive of recent

152 Arthralgia-associated alphaviruses, including chikunguny

153 dbis-group alphavirus closely related to the arthralgia-associated Ockelbo and Girdwood S.A viruses.

154 oup had five grade 3 toxic events, including arthralgia, bone pain, generalised muscle weakness, sync

155 (22.5%), headache by 9 mothers (22.5%), and arthralgia by 8 mothers (20.0%).

156 symptoms disappear after 1 week, but chronic arthralgia can persist for years.

157 more likely to experience soft tissue edema, arthralgias, carpal tunnel syndrome, and gynecomastia an

158 on family with cold-induced urticarial rash, arthralgia, chills, headache and malaise associated with

159 rgy including atopic dermatitis, ichthyosis, arthralgia, chronic diarrhea, disseminated calcifying fi

160 human patient with psoriasiform dermatitis, arthralgias, congenital cataracts, microcephaly, and dev

161 ic descending macular or maculopapular rash, arthralgias, conjunctival injection, and headache; 27% h

162 Each subject had fever, rashes, arthralgia, conjunctivitis, sensorineural deafness, and

163 by intermittent episodes of rash with fever, arthralgias, conjunctivitis, and leukocytosis.

164 ryngitis, upper respiratory tract infection, arthralgia, constipation and urinary tract infection.

165 Nausea, arthralgia, cough, dyspnea, neutropenia, and anemia were

166 GTOV causes fever, prostration, headache, arthralgia, cough, sore throat, nausea, vomiting, diarrh

167 cluding fever, headache, skin rash, myalgia, arthralgia, depression, and coma.

168 Grade 4 toxicities were arthralgia, diarrhea, and vomiting.

169 ce as high as that in the placebo group were arthralgia, diarrhea, pruritus, vomiting, and chest pain

170 Adverse events of transient bone pain, arthralgia, dizziness, hypertension, and hyperuricemia w

171 Grade 3 rash and arthralgia each were reported in 1 romiplostim-treated p

172 More myalgia, arthralgia, edema, and febrile neutropenia occurred on t

173 Children reported fewer arthralgia events than adults (one [<1%] of 303 children

174 The most frequent toxicities were myalgia/arthralgia, fatigue, and triglyceridemia.

175 oderate-to-severe injection-site tenderness, arthralgia, fatigue, malaise) did not.

176 o those observed in other tumor cohorts (eg, arthralgia, fatigue, myalgia, and nausea), and included

177 Fever, myalgias/arthralgias, fatigue, nausea, and headaches were the mos

178 racterized by intermittent episodes of rash, arthralgia, fever and conjunctivitis after generalized e

179 s experience cold-inducible urticarial rash, arthralgia, fever, and fatigue.

180 fatigue (six [24%]), nausea (six [24%]), and arthralgia (five [20%]).

181 tial (> 50%) and sustained improvement in AI arthralgia for both O3-FAs and placebo but found no mean

182 11%]), vitamin D deficiency (four [7%]), and arthralgia (four [7%]) in the tenofovir disoproxil fumar

183 ds increased the sensitivity for identifying arthralgia from 22% to 100%, with a corresponding decrea

184 of clinical presentations of joint-specific arthralgia from this CHIKV cohort.

185 rial fibrillation, bleeding, infections, and arthralgias have been reported.

186 evolocumab-treated patients were back pain, arthralgia, headache, muscle spasms, and pain in extremi

187 onset of signs and symptoms including rash, arthralgia, headache, pruritus, myalgia, and fever.

188 utable to malaria, with fatigue, myalgias or arthralgias, headache, and chills most commonly reported

189 ded peripheral neuropathy in 57%, myalgia or arthralgia in 30%, neutropenia in 53%, neutropenic fever

190 inical trials; however, it induced transient arthralgia in 8% of the vaccinees.

191 pidemics of severe, persistent, debilitating arthralgia in Africa and Asia.

192 HIKV infection and also show that persistent arthralgia in humans may be caused by persistent CHIKV i

193 emonstrate that alphaviruses associated with arthralgia in humans replicate within bone-associated co

194 to-borne alphavirus that causes debilitating arthralgia in humans.

195 virus that causes chronic and incapacitating arthralgia in humans.

196 that causes febrile illness and debilitating arthralgia in humans.

197 orne alphavirus associated with debilitating arthralgia in humans.

198 itoes and causes febrile illness with severe arthralgia in humans.

199 Exercise led to improvement in AI-induced arthralgia in previously inactive breast cancer survivor

200 irus pathogenesis and persistence as well as arthralgias in acute and convalescent filovirus disease.

201 ined whether acupuncture improves AI-induced arthralgias in women with early-stage BC.

202 d in 13 (13%) patients; the most common were arthralgia (in two [2%] patients) and hyponatraemia (in

203 ence of most clinical findings (particularly arthralgia) increased with age, irrespective of previous

204 he PRR for conjunctivitis, eosinophilia, and arthralgia, known adverse effects of dupilumab, were 35.

205 en, symptoms included transient arthritis or arthralgias (<6 weeks duration) in 4 women, arthralgia o

206 .47%] vs 992 individuals [2.07%]; P < .001), arthralgia, myalgia (956 individuals [1.99%] vs 784 indi

207 uded rash, neutropenia, fatigue, neuropathy, arthralgia, myalgia, and diarrhea.

208 y is patients with symptoms of fibromyalgia (arthralgia, myalgia, fatigue) and oral and ocular drynes

209 Other patients develop a syndrome of diffuse arthralgia, myalgia, fatigue, and subjective cognitive d

210 eurological symptoms (extremity paresthesia, arthralgia, myalgia, malaise, pruritus, headache, dizzin

211 e low-grade fever, headache, neck stiffness, arthralgia, myalgia, or fatigue.

212 ed by attacks of fever, sterile peritonitis, arthralgia, myalgia, skin rash, and/or conjunctivitis; s

213 edema and neuropathy, are uncommon, and the arthralgia/myalgia syndrome was not observed.

214 igue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19, and headache.

215 included nausea and emesis, neuropathy, and arthralgia/myalgia.

216 s were most commonly either musculoskeletal (arthralgias, myalgias, and weakness) or pulmonary (cough

217 f fever > 39 degrees C, hypotension, rigors, arthralgias, myalgias, headache, and/or malaise.

218 s, including headache, elevated temperature, arthralgias, myalgias, or fatigue, a larger number of ma

219 most frequent complaints and diagnoses were arthralgia (n = 129 [77.7%]), fatigue (n = 116 [69.8%]),

220 = 1), specified arthritis (n = 11, n = 19), arthralgia (n = 24, n = 7), fibromyalgia (n = 4, n = 11)

221 otein antibody (ACPA)-positive patients with arthralgia (n = 58 serum samples), patients with osteoar

222 Clinical sequelae were common, including arthralgias (n=210, 76%), new ocular symptoms (n=167, 60

223 norexia, asthenia, diarrhea, fever, myalgias/arthralgias, nausea, or vomiting (P < .05) at admission.

224 umatoid arthritis (RA) from non-inflammatory arthralgia (NIA), self-limiting arthritis (SLA), and und

225 s), fatigue (14 [21%]), myalgia (ten [15%]), arthralgia (nine [13%]), and diarrhoea (nine [13%]).

226 vation (nine [6%] vs 13 [8%] vs three [2%]), arthralgia (nine [6%] vs five [3%] vs 15 [10%]), and upp

227 frequent were hypophosphataemia (18 [12%]), arthralgia (nine [6%]), stomatitis (eight [5%]), hyponat

228 Fever, myalgia, rash, night sweats, and arthralgia occurred more frequently in patients with pri

229 Arthralgia occurs in up to 50% of breast cancer survivor

230 rent blistering skin lesions, bronchiolitis, arthralgia, ocular inflammation, enterocolitis, absence

231 arthralgias (<6 weeks duration) in 4 women, arthralgia of indeterminate chronicity in 1 woman, and c

232 iduals diagnosed with the myofascial pain or arthralgia of TMJD.

233 Myalgias and arthralgias of grades 1 to 2 occurred in 16 patients and

234 des of fever, skin rash, abdominal pain, and arthralgia, of whom 1 had elevated levels of serum IgD.

235 subjects with myofascial pain only, 20 with arthralgia only, 157 with both myofascial pain and arthr

236 ficant associations were found for the small-arthralgia-only group.

237 purpura (75%), peripheral neuropathy (52%), arthralgia or arthritis (44%), glomerulonephritis (35%),

238 symptoms including recurrent fever attacks, arthralgia or arthritis and fatigue.

239 tly leading to dose reductions were rash and arthralgia or arthritis.

240 n = 11), and multiple symptoms with minimal arthralgia or myalgia (n = 4, n = 14).

241 hibiting the progression of the disease from arthralgia or UA to RA.

242 onproductive cough, dyspnea, and chills with arthralgias or malaise usually from 4 to 8 hours later s

243 terval [CI], 0.04-2.61, P = 0.3) nor chronic arthralgia (OR, 1.2; 95% CI, 0.2-8.4, P = 0.8) as well a

244 irus infection in children with fever, rash, arthralgia, or conjunctivitis, who reside in or have tra

245 associated with unusual asthenia and diffuse arthralgia over the past 3 weeks.

246 .16), they were less likely to have myalgias/arthralgias (P< .001) and vomiting (P = .02).

247 of hormone-sensitive breast cancer; however, arthralgias (pain and stiffness) contribute to nonadhere

248 m exposed patients were: neck pain, myalgia, arthralgia, paresthesia, sleep disorder, poor appetite a

249 m exposed patients were: neck pain, myalgia, arthralgia, paresthesia, sleep disorder, poor appetite,

250 nificantly enriched in synovial tissues from arthralgia patients.

251 than that among patients with ACPA-positive arthralgia, patients with OA, and healthy control subjec

252 f-of-concept trials of treatment during the 'arthralgia' phase of RA have been completed in the past

253 eported treatment-emergent adverse event was arthralgia (placebo: n = 46 [43.0%]; 100 mug of spriferm

254 diarrhea, constipation, headache, weakness, arthralgia, poor response to antimalarial medications, o

255 ditional symptoms of weakness, headache, and arthralgia primarily involving her bilateral hands, wris

256 broad and varies between types but includes arthralgia, purpura, skin ulcers, glomerulonephritis, an

257 Grade 1-2 diarrhoea, arthralgia, pyrexia, and rash were increased with atezol

258 this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up

259 obin level (n=2); patient refusal (n=2); and arthralgia, rash, and malaise (n=1 each).

260 erse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or

261 wo of headache, retro-orbital pain, myalgia, arthralgia, rash, haemorrhagic manifestations, and leuko

262 most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopeci

263 papules, sometimes edematous, without fever, arthralgia, recurrence or pathergy, inflammatory edemato

264 events, most commonly nausea, headache, and arthralgia, resulted in interruption of PrEp.

265 cids (O3-FAs) can be effective in decreasing arthralgia resulting from rheumatologic conditions and r

266 ommon in older children, with a complaint of arthralgia serving as a significant predictor for infect

267 the impact of exercise versus usual care on arthralgia severity.

268 he most common grade 3-4 adverse events were arthralgia (six [7%] of 89 in the endocrine therapy grou

269 mmatory disease was characterized chiefly by arthralgia, skin rashes, and AA amyloidosis.

270 The toxicities of prinomastat were arthralgia, stiffness, and joint swelling.

271 The most common adverse event reported was arthralgia (stratum I: 94 placebo and 114 anastrozole; s

272 in the development of fever, joint pain, and arthralgia that can become chronic and last for months a

273 rse events were rare; the most frequent were arthralgia (three in the group assigned to fulvestrant p

274 cause profound epidemics of fever, rash, and arthralgia throughout sub-Saharan Africa, Southeast Asia

275 CONCLUSION Women with AI-induced arthralgias treated with TA had significant improvement

276 from anti-citrullinated protein Ab-positive arthralgia, undifferentiated arthritis (UA), early RA, a

277 The most common AEs included arthralgia, upper respiratory tract infection, headache,

278 ommon AEs, incidences of any-grade diarrhea, arthralgia, urinary tract infection, back pain, muscle s

279 ed significantly more stomatitis, myalgia or arthralgia, vomiting, nausea, fatigue, and peripheral ne

280 yndrome with fatigue, headache, myalgia, and arthralgia was highly associated with seropositivity (pr

281 Conversely, arthralgia was more common in CHIKV (94.9%) and FLAV/CHI

282 However, significant persistent arthralgia was observed in patients with low viremia who

283 Arthralgia was one of the most prevalent TMD subgroups i

284 Myofascial pain with arthralgia was significantly associated with trauma (OR

285 Mild arthralgia was the most common persistent symptom.

286 tus was associated with clinical complaints (arthralgia, weakness, loss of vitality, and being diabet

287 e was characterized by higher proportions of arthralgia, weakness, myalgia, and age 41-60 years.

288 and specificity of effusions for identifying arthralgia were 85% and 28%, respectively.

289 ith arm 1, although grade 2/3 neuropathy and arthralgia were less common.

290 Adverse events of nasopharyngitis and arthralgia were reported more frequently with mirikizuma

291 men taking GH + testosterone (32% vs 0%) and arthralgias were more common in men taking GH (41% vs 0%

292 Reversible grade 2 fatigue and myalgias/arthralgias were seen in all pts at 75 micrograms/kg.

293 s, such as cheilitis, headache, and myalgias/arthralgias, were mild or absent.

294 eeks to months of debilitating polyarthritis/arthralgia, which is often poorly managed with current t

295 ute disease characterized by fever, rash and arthralgia, which progresses to severe and chronic arthr

296 on was used to compare those with AI-related arthralgia with those who did not report symptoms, adjus

297 r, a mild to severe disease characterized by arthralgia, with some fatal outcomes described.

298 toms, including cutaneous rash, myalgia, and arthralgia, with the latter sometimes persisting for mon

299 atients with FCAS developed rash, fever, and arthralgias within 1-4 h.

300 Ebola virus disease syndrome in survivors is arthralgia, yet involvement of the joints in acute or co